Abstract:Fatty acid amide hydrolase (FAAH), an amidase-signature family member, is an integral membrane enzyme that degrades lipid amides including the endogenous cannabinoid anandamide and the sleep-inducing molecule oleamide. Both genetic knock out and pharmacological administration of FAAH inhibitors in rodent models result in analgesic, anxiolytic, and antiinflammatory phenotypes. Targeting FAAH activity, therefore, presents a promising new therapeutic strategy for the treatment of pain and other neurological-related or inflammatory disorders. Nearly all FAAH inhibitors known to date attain their binding potency through a reversible or irreversible covalent modification of the nucleophile Ser241 in the unusual Ser-Ser-Lys catalytic triad. Here, we report the discovery and mechanism of action of a series of ketobenzimidazoles as unique and potent noncovalent FAAH inhibitors. Compound 2 , a representative of these ketobenzimidazoles, was designed from a series of ureas that were identified from high-throughput screening. While urea compound 1 is characterized as an irreversible covalent inhibitor, the cocrystal structure of FAAH complexed with compound 2 reveals that these ketobenzimidazoles, though containing a carbonyl moiety, do not covalently modify Ser241. These inhibitors achieve potent inhibition of FAAH activity primarily from shape complementarity to the active site and through numerous hydrophobic interactions. These noncovalent compounds exhibit excellent selectivity and good pharmacokinetic properties. The discovery of this distinctive class of inhibitors opens a new avenue for modulating FAAH activity through nonmechanism-based inhibition.

Design, Synthesis and CoMFA Studies of OEA Derivatives As FAAH Inhibitors

Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase

Design and synthesis of uracil urea derivatives as potent and selective fatty acid amide hydrolase inhibitors

Synthesis of phenoxyacyl-ethanolamides and their effects on fatty acid amide hydrolase activity

Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors

Discovery of Uracil Derivatives as Potent Inhibitors of Fatty Acid Amide Hydrolase

Discovery of Heterocyclic Carbohydrazide Derivatives As Novel Selective Fatty Acid Amide Hydrolase Inhibitors: Design, Synthesis and Anti-Neuroinflammatory Evaluation.

Pharmacophore Modeling and Virtual Screening for the Discovery of New Fatty Acid Amide Hydrolase Inhibitors

Design, Synthesis, and Biological Evaluation of Novel FFA1 Partial Agonists Bearing Oxime Ether Scaffold

Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH)

Synthesis of Oleoylethanolamide Analogues

Visual High-Throughput Screening for Developing a Fatty Acid Amide Hydrolase Natural Inhibitor Based on an Enzyme-Activated Fluorescent Probe

[Synthesis and AchE Inhibitory Activity of 2-Phenoxy-indan-1-one Derivatives].

Homology Modelling and Molecular Dynamics Study of Human Fatty Acid Amide Hydrolase

Synthesis, biological evaluation, and structure activity relationship (SAR) study of pyrrolidine amide derivatives as N -acylethanolamine acid amidase (NAAA) inhibitors.

Design, synthesis, and biological evaluation of oxazolidone derivatives as highly potent N-acylethanolamine acid amidase (NAAA) inhibitors

3D-QSAR Studies on AChE Inhibitory Activities of 2-Phenoxy-indan-1-one Derivatives

Lipophilic Amines As Potent Inhibitors of N-acylethanolamine-hydrolyzing Acid Amidase.

Synthesis and evaluation of 3-(4-(phenoxymethyl)phenyl)propanoic acid and N-phenylbenzenesulfonamide derivatives as FFA4 agonists.

Synthesis, Activity, and Docking Study of Novel Phenylthiazole-Carboxamido Acid Derivatives as FFA2 Agonists

Design, Synthesis and Structure-Activity Relationship Studies of Novel Phenoxyacetamide-Based Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes